Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bologna
Clinical trial register · Italy

Clinical Trials in Bologna, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 51 Bologna 30 Roma 25 Florence 25 Naples 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna306 Istituto Ortopedico Rizzoli107 AstraZeneca46 Eli Lilly and Company30 Janssen Research & Development, LLC26 Clear sponsor filter
Site location
Milan51 Bologna30 Roma25 Florence25 Naples22
All 68 locations
Target enrolment
to

Trials with a site in Bologna

30 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Bologna, Naples, Rozzano
2026-05-28
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Bologna, Milan
2026-04-17
Recruiting
Eli Lilly and Company
Phase 3
150
Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
800
Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bologna, Brescia, Ferrara, Florence, Genova, Milan, Monza, Palermo
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bologna, Catania, Lecce, Lucca, Milan, Modena, Naples, Prato
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Arzignano, Baggiovara, Bologna, Caserta, Ferrara, Ferrara (Cona), Florence, Genova
2025-09-02
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bologna, Milan, Roma, Trieste
2025-07-30
Recruiting
Eli Lilly and Company
Phase 3
290
Bologna, Castellana Grotte, Milan, Padova, Pisa, Rho, Roma, Rozzano
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Bologna, Castellana Grotte, Milan, Padova, Pisa, Rho, Roma, Rozzano
2025-06-26
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Bologna, Milan
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Bologna, Milan
2025-05-20
Active, closed
Eli Lilly and Company
Phase 3
905
Bologna, Catanzaro, Florence, Milan, Naples, Padova, Roma, Torino
2025-04-25
Active, closed
Eli Lilly and Company
Phase 2
143
Bologna, Brescia, Fano, Florence, Gazzi - Messina, Milan, Modena, Monserrato
2024-10-10
Active, closed
Eli Lilly and Company
Phase 3
10,000
Bologna, Ferrara, Genova, Milan, Palermo, Perugia, Pisa, Roma
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
90
Alessandria, Bergamo, Bologna, Florence, Milan, Roma
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Arzignano, Baggiovara, Bologna, Cinisello Balsamo, Ferrara, Florence, Genova, Milan
2024-03-05
Recruiting
Eli Lilly and Company
Phase 3
1,264
Bari, Bologna, Catania, Milan, Naples, Padova, Roma, Rome
2023-12-21
Active, closed
Eli Lilly and Company
Phase 3
160
Bologna, Verona, Messina, Novara
2023-10-16
Active, closed
Eli Lilly and Company
Phase 3
15,374
Bari, Bologna, Como, Ferrara, Florence, Latina, Padova, Palermo
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
8,000
Ancona, Bergamo, Bologna, Brindisi, Candiolo, Florence, Genova, Milan
2022-10-04
Active, closed
Eli Lilly and Company
Phase 2
46
Rome, Bologna
2022-09-20
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bergamo, Bologna, Florence, Milan, Roma, Rome
2021-05-26
Recruiting
Eli Lilly and Company
Phase 2
105
Bologna, Candiolo, Milan, Padova, Roma, Rozzano
2020-01-22
Active, closed
Eli Lilly and Company
Phase 2
234
Roma, Negrar, Bologna, Naples
2016-09-14
Active, closed
Eli Lilly and Company
Phase 3
545
Bari, Aviano, Orbassano, Bologna, Milan, Padova
2015-05-06
Active, closed
Eli Lilly and Company
Phase 3
493
Brindisi, Cona, Genoa, Candiolo, Prato, Negrar, Bergamo, Bologna
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
669
Cona, Rome, Bologna, Padova
2014-07-22
Active, closed
Eli Lilly and Company
Phase 2
110
Bologna, Florence
2012-05-22
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/bologna

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Bologna that also match the filters currently applied.

How many clinical trials are recruiting in Bologna?

17 of the 30 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bologna), 30 studies
PhaseStudiesRecruitingShare
Phase 3201166.7%
Phase 25116.7%
Phase 1226.7%
Phase 4226.7%
Phase 1/2113.3%

Most active sponsors

Lead sponsors with the most studies (Bologna)
Lead sponsorStudiesRecruiting
Eli Lilly and Company3017
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.